Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

A whistleblower accusing Allergan Inc. of engaging in a kickback scheme to increase purchases of “Lap-Band’ obesity devices can advance a portion of his suit toward trial, a Maryland federal judge ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic drugmaker Samsung Bioepis said in a new report on Thursday as the ...

Once Humira biosimilars entered the US markets in 2023, drug revenues declined by 32% for AbbVie. Image credit: Skorzewiak / Shutterstock AbbVie executives say the company’s immunology drugs Skyrizi ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

The Walmart “spark” (the yellow sunburst logo) also received a little makeover. Emphasis on little. The company says it now “exudes the energy of Walmart and remains a beacon that guides ...

While CEO Robert Michael said during the conference that the pharma will “commit less capital” to developing psychiatric therapies, according to Reuters, the BMO note indicates that AbbVie still ...

According to the company, Walmart's updated logo is inspired by his trucker hat. (Luke Frazza/AFP/Getty Images) According to Business Insider, Walmart has rolled out seven different logos prior ...

AbbVie leaders are “disappointed” with poor results from a schizophrenia drug the company acquired last year that led to a $3.5 billion impairment charge, but they say they aren’t completely ...

AbbVie returned to modest growth in 2024 and 2025 figures to be a return to “robust growth," according to the CEO. Through 2029, the company envisions sales will grow in the high-single-digit ...

Wells Fargo & Company increased their price objective on shares of AbbVie to $195.00 and gave the company a “buy” rating in a research report on Tuesday, November 19th.